Kääriä Laura, Lapela Maria, Seppänen Marko, Högerman Mikael, Ruohola Johanna, Ålgars Annika, Noponen Tommi
Department of Clinical Physiology, Nuclear Medicine, Turku PET Centre, and Medical Physics, Turku University Hospital and Wellbeing services county of Southwest Finland and University of Turku, Turku, Finland.
Department of Oncology, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, Finland.
EJNMMI Phys. 2024 Nov 29;11(1):101. doi: 10.1186/s40658-024-00701-8.
Continuously monitored external dose-rate signals from remote dose-rate meters (DRMs) were analyzed to determine the effective half-life (T) of I in differentiated thyroid cancer (DTC) patients. The aim is to gain novel understanding of the excretion of radioactive iodine (RAI) in DTC patients and to demonstrate that a remote DRM system can be reliably used for real-time monitoring of external dose-rates of DTC patients.
110 DTC patients who received postoperative RAI therapy between September 2018 and February 2023 in Turku University Hospital were studied retrospectively. The external dose-rates of the patients were continuously monitored during their hospitalization with a remote DRM fixed in the ceiling of the isolation room. Generalized linear mixed model (GLMM) was used to analyse the association between logarithmical T and patient characteristics.
The median T for all patients was 12.60 h (Q1: 10.35; Q3: 14.75 h). Longer Ts were associated with higher BMI (p = 0.004), lower GFR (p < 0.001), and diabetes (p = 0.007). Our study also revealed that neither age nor subsequent RAI therapies have a significant impact on the whole body T (p = 0.522 and p = 0.414, respectively).
Patients with higher BMI, decreased GFR, or diabetes have a longer whole-body T of I. Ceiling-mounted remote DMRs can reliably be used to determine patient's T. Since T values vary among patients, ceiling-mounted meters can be used to optimize the length of radiation isolation period at the hospital while improving patient comfort and staff efficiency.
分析来自远程剂量率仪（DRM）的连续监测的外部剂量率信号，以确定分化型甲状腺癌（DTC）患者体内碘的有效半衰期（T）。目的是加深对DTC患者放射性碘（RAI）排泄的新认识，并证明远程DRM系统可可靠地用于实时监测DTC患者的外部剂量率。
回顾性研究了2018年9月至2023年2月在图尔库大学医院接受术后RAI治疗的110例DTC患者。在患者住院期间，使用安装在隔离室天花板上的远程DRM对其外部剂量率进行连续监测。采用广义线性混合模型（GLMM）分析对数T与患者特征之间的关联。
所有患者的中位T为12.60小时（第一四分位数：10.35；第三四分位数：14.75小时）。T较长与较高的体重指数（BMI）（p = 0.004）、较低的肾小球滤过率（GFR）（p < 0.001）和糖尿病（p = 0.007）相关。我们的研究还表明，年龄和后续的RAI治疗对全身T均无显著影响（分别为p = 0.522和p = 0.414）。
BMI较高、GFR降低或患有糖尿病的患者体内碘的全身T较长。天花板安装的远程DMR可可靠地用于确定患者的T。由于T值因患者而异，天花板安装的剂量率仪可用于优化医院的辐射隔离期长度，同时提高患者舒适度和工作人员效率。
